Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | PDE9A | O76083 | 1/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060767 | 0.89 | HPGD (0.55) | ARALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL3052703 | 0.89 | HPGD (0.55) | ARALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL27440350 | 0.87 | ALDH1A1 (0.55) | ARALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL29961535 | 0.87 | ALDH1A1 (0.40) | ARALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL15018232 | 0.86 | ALDH1A1 (0.49) | ARALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL4854571 | 0.80 | ALDH1A1 (0.49) | ALDH1A1LMNAKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL27440039 | 0.78 | NAMPT (0.43) | ARALDH1A1LMNATSHRKMT2A | |
| SCHEMBL15018977 | 0.77 | AR (0.48) | ARALDH1A1LMNASMN1; SMN2TSHR | |
| SCHEMBL14193672 | 0.75 | ALDH1A1 (0.76) | ALDH1A1LMNAKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL27888661 | 0.75 | ALDH1A1 (0.49) | ARALDH1A1LMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791142-B1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | US HEALTH (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-2791142-B1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | US HEALTH (US) | 2019-07-03 | — | — | EP | disclosed |
| US-10301314-B2 | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301314-B2 | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-05-28 | — | — | US | disclosed |
| US-9877966-B1 | Combination therapy for the inhibition of metastasis and tumorigenesis | OLIVA EUGENE J (US) | 2018-01-30 | — | — | US | disclosed |
| US-9877966-B1 | Combination therapy for the inhibition of metastasis and tumorigenesis | OLIVA EUGENE J (US) | 2018-01-30 | — | — | US | disclosed |
| US-9877966-B1 | Combination therapy for the inhibition of metastasis and tumorigenesis | OLIVA EUGENE J (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170260192-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260192-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260192-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-14 | — | — | US | disclosed |
| US-20140323438-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | NORTHWESTERN UNIVERSITY | 2014-10-30 | — | — | US | disclosed |
| US-20140323438-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | NORTHWESTERN UNIVERSITY | 2014-10-30 | — | — | US | disclosed |
| US-20140323438-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | NORTHWESTERN UNIVERSITY | 2014-10-30 | — | — | US | disclosed |
| EP-2791142-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013090912-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090912-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-06-20 | — | — | WO | disclosed |
| US-6096749-A | ANTITUMOR, EPIDERMAL GROWTH FACTOR | NOVARTIS CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-5686457-A | FOR TREATING A TUMOR OR PSORIASIS | NOVARTIS CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0682027-B1 | Pyrrolopyrimidine derivatives with antiproliferative action | CIBA GEIGY AG (CH) | 1997-10-15 | — | — | EP | disclosed |
| EP-0682027-A1 | Pyrrolopyrimidine derivatives with antiproliferative action | CIBA-GEIGY AG (CH) | 1995-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323438-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | PGF, BRCA1, RB1 | AR 334/4885ALDH1A1 192/4885LMNA 424/4885 |
| US-20170260192-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | PGF, BRCA1, RB1 | AR 334/4885ALDH1A1 192/4885LMNA 424/4885 |
| US-10301314-B2 | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis | PGF, BRCA1, RB1 | AR 334/4885ALDH1A1 192/4885LMNA 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.